Table II.

Median percent reduction in seizure frequency and percentage of patients with at least 50% reduction in seizure frequency (vs baseline) in three double-blind, parallel-group, placebo-controlled, adjunctive-therapy trials of lacosamide (LCM) in patients with refractory partial-onset seizures

Study	No. of patients	Duration of treatment (titration/maintenance)	Treatment	Median % reduction in seizure frequency vs baseline (p-value)	% of patients with ≥ 50% reduction in seizure frequency vs baseline (p-value)
Ben-Menachem et al.[58]	418	6 wk/12 wk	Placebo	10	21.9
			LCM 200 mg/day	26 (NS)	32.7 (NS)
			LCM 400 mg/day	39 (p = 0.002)	41.1 (p = 0.004)
			LCM 600 mg/day	40 (p = 0.008)	38.1 (p = 0.014)
Chung et al.[61]	405	6 wk/12 wk	Placebo	20.8	18.3
			LCM 400 mg/day	37.3 (p = 0.008)	38.3 (p = 0.0004)
			LCM 600 mg/day	37.8 (p = 0.006)	41.2 (p = 0.0005)
Halász et al.[60]	485	4 wk/12 wk	Placebo	20.5	25.8
			LCM 200 mg/day	35.3 (p = 0.02)	35.0 (NS)
			LCM 400 mg/day	36.4 (p = 0.03)	40.5 (p = 0.01)

NS = not statistically significant (vs placebo).